Camizestrant demonstrated highly statistically significant improvement in PFS in 1L advanced HR+ve breast cancer with an emergent ESR1 tumour mutation in SERENA-6 Ph 3 trial March 4, 2025
First Patient Dosed in the WIN-B Trial of Debio 0123 & Trodelvy® in Advanced Breast Cancer March 3, 2025
Datroway (datopotamab deruxtecan) approved in the US for patients with previously treated metastatic HR+ve, HER2-neg breast cancer January 21, 2025
DATROWAY Approved in Japan for Patients with Previously Treated Unresectable or Recurrent HR+ve, HER2neg Breast Cancer January 7, 2025
Olema Oncology Announces New CTA and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement December 4, 2024
Kisqali receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence December 4, 2024
Incyclix Bio and Lilly to test INX-315 + Verzenio and Fulvestrant in HR+/HER2- Breast Cancer November 26, 2024
ALISCA-Breast1 Ph 2 Trial of Alisertib initiated in HR+ve, HER2-Negative Metastatic Breast Cancer November 26, 2024
Positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer October 22, 2024
FAILED TRIAL: Datopotamab deruxtecan did not achieve statistical significance for OS vs chemo in patients with metastatic HR+, HER2-low or neg breast cancer in TROPION-Breast01 Ph 3 trial September 24, 2024
FDA approves Kisqali to reduce risk of recurrence in people with HR+/HER2- early breast cancer September 24, 2024
Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful PFS announced September 17, 2024
Enrollment of 80mg PK Run-In Cohort in Ph 2 EVANGELINE Trial of (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer Completed July 30, 2024
Type C meeting with FDA supporting the planned potential registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC) concluded July 1, 2024
FDA grants Priority Review to inavolisib for advanced HR+ve, HER2-neg breast cancer with a PIK3CA mutation June 4, 2024
Updated Clinical Data from Ph 1b Trial of Vepdegestrant + Palbociclib (IBRANCE) Announced May 21, 2024
Datopotamab deruxtecan BLA accepted in the US for patients with previously treated metastatic HR+ve, HER2-neg breast cancer April 8, 2024
FDA Allows to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer March 26, 2024
Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous NSCLC or HR+, HER2 Negative Breast Cancer March 12, 2024
Preliminary DCR of 61% reported in evaluable Ph 2 advanced breast cancer patients treated with Bria-IMT February 26, 2024
First Patient Dosed in Ph 1b/2 Trial of Samuraciclib + Vepdegestrant in Patients with Advanced Breast Cancer February 26, 2024
